StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.33−0.01 (-4.24%)

Close on Nov 17, 2026Market cap $4.85MP/E –Yield –

Tempest Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tempest Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$20.73M. For fiscal 2025 it was -$26.82M. The highest annual figure on record is -$11.16M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.82M–
FY2024Dec 31, 2024-$33.03M–
FY2023Dec 31, 2023-$27.36M–
FY2022Dec 31, 2022-$31.07M–
FY2021Dec 31, 2021-$25.96M–
FY2020Dec 31, 2020-$19.02M–
FY2019Dec 31, 2019-$41.22M–
FY2018Dec 31, 2018-$23.65M–
FY2017Dec 31, 2017-$20.34M–
FY2016Dec 31, 2016-$61.73M–
FY2015Dec 31, 2015-$50.29M–
FY2014Dec 31, 2014-$30.59M–
FY2013Dec 31, 2013-$18.09M–
FY2012Dec 31, 2012-$11.16M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.78M–
Q1 FY2026Mar 31, 2026-$7.60M–
Q4 FY2025Dec 31, 2025-$3.57M–
Q3 FY2025Sep 30, 2025-$6.78M–
Q2 FY2025Jun 30, 2025-$8.43M–
Q1 FY2025Mar 31, 2025-$8.04M–
Q4 FY2024Dec 31, 2024-$10.15M–
Q3 FY2024Sep 30, 2024-$10.18M–
Q2 FY2024Jun 30, 2024-$5.51M–
Q1 FY2024Mar 31, 2024-$7.19M–
Q4 FY2023Dec 31, 2023-$6.18M–
Q3 FY2023Sep 30, 2023-$6.49M–
Q2 FY2023Jun 30, 2023-$6.39M–
Q1 FY2023Mar 31, 2023-$8.30M–
Q4 FY2022Dec 31, 2022-$6.48M–
Q3 FY2022Sep 30, 2022-$9.07M–
Q2 FY2022Jun 30, 2022-$8.41M-6725.2%
Q1 FY2022Mar 31, 2022-$7.11M–
Q4 FY2021Dec 31, 2021-$7.99M–
Q3 FY2021Sep 30, 2021-$11.79M–
Q2 FY2021Jun 30, 2021$127.00K+217.5%
Q1 FY2021Mar 31, 2021-$6.31M–
Q4 FY2020Dec 31, 2020-$4.27M–
Q3 FY2020Sep 30, 2020-$4.62M–
Q2 FY2020Jun 30, 2020$40.00K–
Q1 FY2020Mar 31, 2020-$10.16M–
Q4 FY2019Dec 31, 2019-$11.69M–
Q3 FY2019Sep 30, 2019-$8.36M–
Q2 FY2019Jun 30, 2019-$10.57M–
Q1 FY2019Mar 31, 2019-$10.60M–
Q4 FY2018Dec 31, 2018-$9.23M-153.5%
Q3 FY2018Sep 30, 2018-$4.72M–
Q2 FY2018Jun 30, 2018-$4.70M–
Q1 FY2018Mar 31, 2018-$5.00M–
Q4 FY2017Dec 31, 2017$17.24M–
Q3 FY2017Sep 30, 2017-$10.30M–
Q2 FY2017Jun 30, 2017-$12.09M–
Q1 FY2017Mar 31, 2017-$15.19M–
Q4 FY2016Dec 31, 2016-$14.97M–
Q3 FY2016Sep 30, 2016-$15.44M–

More Tempest Therapeutics figures

See a number that looks wrong?